Strong line-up at crowded BioCapital Europe
The 21st edition of BioCapital Europe, an investor conference hosted by EQT Life Science in Amsterdam, brought together venture capital and biotech leaders from across Europe for an intense day of networking and insights into the latest scientific and financial trends shaping the sector.
The conference opened with a keynote address by Bloomberg healthcare analyst Sam Fazeli, who painted a mixed image of caution and optmimism regarding the current investment landscape amidst economic and geopolitical uncertainties, underscoring the increasing importance of innovative financing models and strategic collaborations going forward.
Pitches and investor insights
In addition to multi-track pitching sessions featuring around 40 bio- and med tech companies, the agenda also offered expert discussions centered around hot investment spaces such as the rapidly advancing radiopharmaceutical sector. A panel featuring industry leaders from Novartis, Ariceum Therapeutics, PanTera, and Essen University Hospital delved into the transformative potential of radiopharma, highlighting the sector’s strong clinical momentum but also addressing key challenges, such as supply chain complexities and potential regulatory hurdles.
A Swedish trailblazer in focus
A major Swedish highlight of the conference was a keynote address by Professor Lars Lannfelt, co-founder of BioArctic, whose groundbreaking research on Alzheimer’s disease has enabled the remarkable journey of lecanemab, an antibody therapy targeting soluble amyloid-beta protofibrils, from its initial discovery to clinical implementation and ongoing global roll-out.
Voices in the crowd
As media partner to the event, BioStock had a chance to interview several company executives, many of whom had attended the conference multiple times before. We also spoke to René Kuijten, Head of EQT Life Sciences and main host who took a short break, while enjoying the conference surrounded by investors and entrepreneurs discussing new partnerships and funding opportunities.
A selection of the interviews can be found below.
Interview: Renee Kuijten, Head of EQT Life Sciences.
Interview: Fiorella Kotsias, CSO Egle Therapeutics and Jean-Baptiste Célard, Namsen Capital.
Interview: Dominik Schumacher, CEO Tubulis.
Interview: Micah Mackinson, CEO Vico Therapeutics.
Interview: Henric Bjarke, Tenpoint Therapeutics.
Interview: Kasper Roet, CEO QurAlis.
Interview: Manfred F. Rüdinger, CEO Ariceum Therapeutics.
Interview: Ruben de Francisco, CEO Onera Health.
Interview: Roeland Pelgrims, CEO Nobi Smart Lights.
Interview: John Glasspool, CEO VarmX.
Interview: Pierre d’Epenoux, CEO and Stephan Braun, CMO Imcheck Therapeutics.
